\nVyome Holdings, Inc. (Nasdaq: HIND, \u201cVyome\u201d), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports financial results for the second quarter ended June 30, 2026, and provides a corporate update.<\/p>\n
\nKrishna Gupta, Chairman, Vyome Holdings, said, \u201cVyome continues to execute with focus and discipline across its development programs while maintaining a methodical and conservative approach to capital allocation. During the quarter, we advanced our lead VT-1953 program, broadened our pipeline through the Impetis agreement and continued to strengthen our intellectual property portfolio. With a strong balance sheet and disciplined capital structure, we believe Vyome is well positioned to pursue its development priorities and create long-term shareholder value.\u201d<\/p>\n
\nVenkat Nelabhotla, Vyome President and Chief Executive Officer, stated, \u201cVT-1953 remains our lead priority. The Phase 2 data presented this year demonstrated statistically significant improvements in malodor, the patient-reported impact of malodor on daily life, and lesion pain, with no treatment-emergent adverse events reported. In March 2026, we submitted a pre-IND briefing package to the FDA that included our proposed pivotal clinical study strategy for the treatment of malodor and other symptoms associated with malignant fungating wounds. During the second quarter of 2026, the Company received the FDA\u2019s written response on the proposed clinical development program. The Company is incorporating the FDA\u2019s feedback, preparing the appropriate supporting package, and plans to continue its engagement with the FDA through a Type C meeting to further advance the clinical development program.<\/p>\n
\n\u201cAt the same time, we are selectively building additional opportunities around our core immuno-inflammatory strategy. Our agreement with Impetis adds two selective JAK inhibitor assets and provides potential access to important autoimmune and inflammatory disease categories. We intend to advance these opportunities in a disciplined manner with non-dilutive methods while keeping VT-1953 as our primary development focus. Importantly, we continue to maintain a clean capital structure with no debt, no preferred stock, and no toxic financing instruments. We believe this combination of focused clinical execution, pipeline optionality, and financial discipline provides a strong foundation for long-term shareholder value,\u201d concluded Mr. Nelabhotla.<\/p>\n
Second Quarter 2026 and Recent Corporate Highlights<\/i><\/b><\/p>\n Financial Results for the Quarter Ended June 30, 2026<\/b><\/p>\n\n
\n
\n
\n
\n
\n
\n
\n
\n